These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase. Montenegro-Garreaud X; Miranda RN; Reynolds A; Tang G; Wang SA; Yabe M; Wang W; Fang L; Bueso-Ramos CE; Lin P; Medeiros LJ; Lu X Hum Pathol; 2017 Jul; 65():147-156. PubMed ID: 28551329 [TBL] [Abstract][Full Text] [Related]
5. Myeloid/lymphoid neoplasm with CEP110-FGFR1 fusion: An analysis of 16 cases show common features and poor prognosis. Chen M; Wang K; Cai X; Zhang X; Chao H; Chen S; Shen H; Wang Q; Zhang R Hematology; 2021 Dec; 26(1):153-159. PubMed ID: 33491601 [No Abstract] [Full Text] [Related]
6. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. Hernández-Boluda JC; Pereira A; Zinger N; Gras L; Martino R; Nikolousis E; Finke J; Chinea A; Rambaldi A; Robin M; Saccardi R; Natale A; Snowden JA; Tsirigotis P; Vallejo C; Wulf G; Xicoy B; Russo D; Maertens J; Daguindau E; Lenhoff S; Hayden P; Czerw T; McLornan DP; Yakoub-Agha I Bone Marrow Transplant; 2022 Mar; 57(3):416-422. PubMed ID: 35066569 [TBL] [Abstract][Full Text] [Related]
7. Myeloid and lymphoid neoplasm with abnormalities of FGFR1 presenting with trilineage blasts and RUNX1 rearrangement: a case report and review of literature. Kumar KR; Chen W; Koduru PR; Luu HS Am J Clin Pathol; 2015 May; 143(5):738-48. PubMed ID: 25873510 [TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement. Umino K; Fujiwara SI; Ikeda T; Toda Y; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y Hematology; 2018 Sep; 23(8):470-477. PubMed ID: 29486661 [TBL] [Abstract][Full Text] [Related]
9. Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/ Manur R; Sung PJ; Loren AW; Ritchie EK; Frank D; Bagg A; Geyer JT; Bogusz AM Leuk Lymphoma; 2020 Feb; 61(2):450-454. PubMed ID: 31524018 [No Abstract] [Full Text] [Related]
10. [The 8p11 myeloproliferative syndrome: a review of recent literature]. Kirito K Rinsho Ketsueki; 2019; 60(9):1157-1165. PubMed ID: 31597839 [TBL] [Abstract][Full Text] [Related]
11. Olverembatinib for myeloid/lymphoid neoplasm associated with eosinophilia and Yan Y; Qu S; Liu J; Li C; Yan X; Xu Z; Qin T; Jia Y; Pan L; Gao Q; Jiao M; Li B; Gale RP; Xiao Z Leuk Lymphoma; 2023 Sep; 64(9):1605-1610. PubMed ID: 37354441 [No Abstract] [Full Text] [Related]
12. Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor. Verstovsek S; Subbiah V; Masarova L; Yin CC; Tang G; Manshouri T; Asatiani E; Daver NG Ann Oncol; 2018 Aug; 29(8):1880-1882. PubMed ID: 29767670 [No Abstract] [Full Text] [Related]
13. Myeloid/Lymphoid Neoplasm with FGFR1 Rearrangement Presenting with Polycythemia Vera and T-cell Acute Lymphoblastic Leukemia. Marinelli LM; Romain JT; Ehman W; Ortega V; Velagaleti G; Gibbons TF; Nazario-Toole A; Holmes AR Cancer Genet; 2023 Aug; 276-277():43-47. PubMed ID: 37480761 [TBL] [Abstract][Full Text] [Related]
14. Systemic mastocytosis with associated myeloproliferative neoplasm with t(8;19)(p12;q13.1) and abnormality of FGFR1: report of a unique case. Duckworth CB; Zhang L; Li S Int J Clin Exp Pathol; 2014; 7(2):801-7. PubMed ID: 24551307 [TBL] [Abstract][Full Text] [Related]
15. Rare and potentially fatal - Cytogenetically cryptic TNIP1::PDGFRB and PCM1::FGFR1 fusion leading to myeloid/lymphoid neoplasms with eosinophilia in children. Berking AC; Flaadt T; Behrens YL; Yoshimi A; Leipold A; Holzer U; Lang P; Quintanilla-Martinez L; Schlegelberger B; Reiter A; Niemeyer C; Strahm B; Göhring G Cancer Genet; 2023 Apr; 272-273():29-34. PubMed ID: 36657267 [TBL] [Abstract][Full Text] [Related]
16. Pemigatinib: First Approval. Hoy SM Drugs; 2020 Jun; 80(9):923-929. PubMed ID: 32472305 [TBL] [Abstract][Full Text] [Related]
17. FGFR1 translocation with concurrent myeloproliferative neoplasm, systemic mastocytosis, and lymphoblastic lymphoma: a case report. Chang K; Liu JH; Yu SC; Lin CW Hum Pathol; 2018 Apr; 74():114-121. PubMed ID: 29107667 [TBL] [Abstract][Full Text] [Related]
18. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1. Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675 [TBL] [Abstract][Full Text] [Related]
19. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Chen J; Deangelo DJ; Kutok JL; Williams IR; Lee BH; Wadleigh M; Duclos N; Cohen S; Adelsperger J; Okabe R; Coburn A; Galinsky I; Huntly B; Cohen PS; Meyer T; Fabbro D; Roesel J; Banerji L; Griffin JD; Xiao S; Fletcher JA; Stone RM; Gilliland DG Proc Natl Acad Sci U S A; 2004 Oct; 101(40):14479-84. PubMed ID: 15448205 [TBL] [Abstract][Full Text] [Related]